Poor
Not Aligned
Patient Risk:
Low
Summary
All extracted claims pertain to patent status and market rights in Mexico rather than FDA-approved prescribing information. The provided content is not present in the FDA label and does not describe label-approved indications, dosing, safety, or other on-label content.
Category Scores
Accurate Statements
Unsupported Statements
Sumitomo Pharma Co., Ltd. has secured a set of patent filings in Mexico that cover the oral gonadotropin‑releasing hormone (GnRH) antagonist relugolix, its formulation, and its therapeutic uses.
Not supported by FDA-approved prescribing information (absent from label).
The filings are under the Mexican Patent Office (IMPI) and include claims on the chemical structure and pharmacological application.
Not supported by FDA-approved prescribing information (absent from label).
The active ingredient relugolix itself.
Not supported by FDA-approved prescribing information (absent from label).
Oral dosage forms and delivery systems.
Not supported by FDA-approved prescribing information (absent from label).
Methods of using relugolix to treat prostate cancer and other hormone‑dependent conditions.
Not supported by FDA-approved prescribing information (absent from label).
These patents are intended to give Sumitomo exclusive rights to manufacture, distribute, and market relugolix in Mexico.
Not supported by FDA-approved prescribing information (absent from label).
The earliest Mexican patent application dates to the early 2010s.
Not supported by FDA-approved prescribing information (absent from label).
Subsequent priority filings in 2012 and 2013.
Not supported by FDA-approved prescribing information (absent from label).
The most recent application, which includes an extended claim set, was published in 2017.
Not supported by FDA-approved prescribing information (absent from label).
The patents are still within the typical 20‑year term from the filing date.
Not supported by FDA-approved prescribing information (absent from label).
Sumitomo Pharma remains the original applicant.
Not supported by FDA-approved prescribing information (absent from label).
The commercial rights to relugolix in many markets—including Mexico—are currently held by GSK (GlaxoSmithKline), which acquired the global rights from Sumitomo in 2017.
Not supported by FDA-approved prescribing information (absent from label).
GSK has licensed the Mexican patents back to Sumitomo for local marketing, so both entities have overlapping claims.
Not supported by FDA-approved prescribing information (absent from label).
The Mexican Patent Office’s online database allows you to search by applicant name ("Sumitomo Pharma Co., Ltd.") or by the drug’s name "relugolix."
Not supported by FDA-approved prescribing information (absent from label).
DrugPatentWatch.com aggregates this data and provides up‑to‑date status reports, including expiration dates and any litigation or oppositions.
Not supported by FDA-approved prescribing information (absent from label).
Visiting the site and searching for “relugolix” under the “Mexico” jurisdiction will give the full filing history and current legal status.
Not supported by FDA-approved prescribing information (absent from label).
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
Evaluation focuses on patent/ownership information not related to patient safety or label-based risk. No safety claims are made.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Not Aligned
Primary Issue
Content pertains to patent status and market rights rather than FDA-approved prescribing information.
Suggested Improvement
If evaluating label alignment, restrict content strictly to FDA-approved label claims (indications, dosing, contraindications, warnings/precautions, adverse reactions, etc.) and avoid non-label patent/market information.